Current Members
Staff
Suzy Gustafson
Operations Administrator
Ramesh Mukkamala
Associate Research Scientist
Design and development of Fibroblast Activation Protein (FAP) targeted ligands and their applications for delivery of attached imaging and therapeutic agents to cancers and fibrotic diseases.
Sudarsan Reddy Kasireddy
Associate Research Scientist
Design, synthesis, and evaluation of ligand-targeted oligonucleotides and therapeutic agents for the treatment of cancer and fibrotic diseases.
Suilan Zheng
Research Scientist
Design of novel CAR T cell (Chimeric Antigen Receptor T cell) based immunotherapies for solid tumors that can be sensitively and continuously regulated following their infusion into cancer patients.
Suresh Yarlagadda
Associate Research Scientist
Design, Synthesis, and Biological Evaluation of Novel Spleen Tyrosine Kinase Inhibitors for the Treatment of Autoimmune, Inflammatory and Cancerous Diseases.
Mahesh
Research Scientist
Development of Folate-Targeted Steroids and Vaccine Conjugates for the Treatment of Autoimmune, Inflammatory, and Cancer Disorders.
Ananda Kumar Kanduluru
Research Scientist
Design and development of targeted therapeutic agents for multiple diseases including infectious (anti viral’s), cancer and autoimmune diseases.
Visiting Scholars
Stewart Low, Executive Director at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Cultivate an R&D pipeline from preclinical studies through clinical development and regulatory submission.
Mary Niedrauer, Senior Director at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Development of drug candidates from discovery through early clinical trials across disease states, including cancer, autoimmune, and fibrotic diseases.
Losha DaSol Jung, Scientist I at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Lead the design and execution of comprehensive preclinical studies in in vitro, ex vivo, and in vivomodels to support the development of novel targeted cancer therapies.
Reuben Dass, Scientist I at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Design, optimization, and evaluation of novel therapeutic agents, with a focus on enhancing their selectivity, efficacy, and pharmacokinetic properties through detailed structure–activity relationship (SAR) studies.
Evan Shadoff, Research Associate at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Design, optimization, and execution of experiments in support of a targeted small molecule DNA damage repair inhibitor for the treatment of radioresistant prostate cancer, including in vitro and in vivo protocols for drug screening, efficacy, and tolerability studies.
Jennifer Clark, Research Associate for Low Institute for Therapeutics (LIFT)
Visiting Scholar
Development and execution of preclinical studies in order to to precisely treat a wide range of diseases by preferentially targeting diseased tissue.
Neel Parekh, Research Associate at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Developing next-generation bone-targeted radioligand therapy to improve outcomes in bone metastasis.
Nithin Raj Senthil Raj, Research Associate at Low Institute for Therapeutics (LIFT)
Visiting Scholar
Designs and conducts preclinical experiments involving in vitro assay development, mechanistic studies, and assists in vivo studies to advance drug discovery and development in targeted cancer therapeutics.
Post-Doctorates
Ranjith Kumar Gadi
Post-Doctorate
Extending the half-life of therapeutics through the development of RBC binders and plasma protein binders, as well as design and synthesizing stable linkers for FRET-based small-molecule probes.
Ronard Kwizera
Post-Doctorate
Design, synthesis, and evaluation of therapeutic activity of targeted immunotherapies for difficult-to-treat human diseases such as cancer.
Terungwa Iorkula (Jasper)
Post-Doctorate
Design, synthesis and evaluation of GLP-1Ra-DYRK1A conjugates for treatment of diabetes.
Ting Chen
Post-Doctorate
Development and optimization of novel radiotherapeutic and immunotherapeutic strategies, including the design and synthesis of functional agents and the assessment of their therapeutic potential in the treatment of cancer.
Graduate Students
Jacob David Newey
Ph.D. Graduate Student
Design, synthesis, and testing of targeted antigens for the treatment of autoimmune diseases and allergies.
Charles Key Stone
Ph.D. Graduate Student
Development, synthesis and testing of small molecule immunotherapies targeting Natural Killer cells and Neutrophils for the treatment of Cancer and Autoimmune diseases.
Pranav Ballaney
Ph.D. Graduate Student
Computational design, synthesis, and preclinical evaluation immune cell engagers with applications in cancer and autoimmune disorders.
Zhixia Chi
Ph.D. Graduate Student
Design and develop new ligand-conjugated antisense oligonucleotides for preclinical studies of fibrotic diseases, with a focus on renal fibrosis.
Mohammed Yusuf Al Amin
Ph.D. Graduate Student
Development of cytokine inhibitory drugs targeting
- tumor associated macrophages (TAMs) and cancer associated fibroblasts (CAFs) in the management of cancer, and
- activated macrophages and fibroblasts in the treatment of fibrosis.
Shomoita Sayed
Ph.D. Graduate Student
Development and Optimization of targeted novel therapeutics for the treatment of retinal diseases.
Yingqi Chen
Ph.D. Graduate Student
Design and development of an antigen, targeting ligand, and adjuvant integrated into a single universal dendritic cell (DC) targeting vaccine for use in cancer and infectious disease models.
Hunter Hutson
Ph.D. Graduate Student
Design and development of small molecule targeted therapeutics for the treatment of CNS diseases.
Kavya Ananthaswamy
Ph.D. Graduate Student
Mohammed Sazzadul Bari
Ph.D. Graduate Student
Designing and development of novel therapeutics for treating different fibrotic diseases and cancer by creating drug conjugates that specifically target proteins overexpressed on activated fibroblasts, aiming to maximize therapeutic efficacy while minimizing off-target interactions.
Qingshi Chen
Ph.D. Graduate Student
Cameron Smith
Ph.D. Graduate Student
Development and characterization of small molecule drug conjugates for targeting and repolarizing TAMs in the tumor microenvironment for the treatment of cancer.
Haowei Xu
Ph.D. Graduate Student
Development of targeted therapeutics to alleviate obesity and renal transplant rejection.
Roman Slowinski
Ph.D. Graduate Student
Developing molecular shuttling systems to transport therapeutics across the Blood-Brain Barrier.
Archit Gupta
Ph.D. Graduate Student
Advancing targeted drug and RNA-based therapies for cancer treatment.